Check out your Company Bowl for anonymous work chats.
Venclaxta monotherapy has shown high response rates and well tolerated safety profile in patients with chronic lymphocytic leukaemia (CLL). At the 22nd European Hematology Association (EHA) Annual Congress, Roche presented data from multiple studies and highlighted its potential in treatment of CLL, acute myeloid leukaemia and multiple myeloma. For more information visit : http://glassdoor.com/slink.htm?key=vQ41u
Learn how to accelerate innovation in #Pharma using #ArtificialIntelligence, #MachineLearning and #BigData. Gaurav Tripathi http://glassdoor.com/slink.htm?key=vQ41H
Roche's Alecensa (alectinib) clears the Phase III trial as first-line therapy for patients with ALK-positive advanced non small cell lung cancer (NSCLC) For more information visit : http://glassdoor.com/slink.htm?key=vQ41R
Boehringer Ingelheim's BI-695501 is currently under review by both, European Medicines Agency and FDA . With the positive phase III results, BI-695501, if approved, would give high quality and cost effective treatment options to Rheumatoid Arthritis patients. For more information visit : http://glassdoor.com/slink.htm?key=vQ41Y
Diabetes is considered to be one of the top reasons for kidney failure. More than seven million people in the U.S.A suffer from diabetic kidney disease. Will Bayer's Finerenone beat the new breakthrough therapies in Diabetic Kidney Disease? Daiichi Sankyo, Inc. Eli Lilly, Pfizer Know more here : http://glassdoor.com/slink.htm?key=vQ41y
Pfizer's breast #cancer drug, 'Ibrance' is the first FDA approved CDK 4/6 inhibitor. The advantages are enormous and Ibrance seems to have gained from it, demonstrating a sale of $723 million in 2015 and rapid rise to $2.1 billion in 2016. Eli Lilly Novartis For more information visit : http://glassdoor.com/slink.htm?key=vQ410
Pfizer's breast #cancer drug, 'Ibrance' is the first FDA approved CDK 4/6 inhibitor. The advantages are enormous and Ibrance seems to have gained from it, demonstrating a sale of $723 million in 2015 and rapid rise to $2.1 billion in 2016. Eli Lilly Novartis For more information visit : http://glassdoor.com/slink.htm?key=vQ41c
Do you know what Alzheimer disease publications pattern is reflecting? Find out the trends, its CAGR, and countries that are researching and publishing more about Alzheimer, here: http://glassdoor.com/slink.htm?key=vQ41l
FDA first “site-agnostic” approval for a cancer drug (Keytruda) indicates a potential shift in cancer treatment approach with PD-1 inhibitors. Merck, Pfizer, Boehringer Ingelheim. For more information about the drug visit http://glassdoor.com/slink.htm?key=vQ41e now. http://glassdoor.com/slink.htm?key=vQ414
Read our CTO, Gaurav Tripathi's views on ways Big Data and Analytics are Making Big Changes in Healthcare. Know more - http://glassdoor.com/slink.htm?key=vQ41i
